THABOR THERAPEUTICS
Will attend BioEquity on 15-16 May 2023
Develops innovative treatments for human mucosal inflammatory diseases by preventing inflammation and fibrosis, as well as restoring epithelial integrity
SCIENCE
A new target for mucosal inflammatory diseases
Thabor therapeutics is a biotechnology company focused on treating human mucosal inflammatory diseases by inhibiting a new target that could be implied in the early inflammatory process and the recruitment of innate immunity cells. The company aims to develop first-in-class drugs targeting specifically a new class of proteins involved in the resolution of the inflammation.
MANAGEMENT TEAM
The company is managed by a highly-experienced and complementary team.
JÉRÉMIE MARIAU
CEO
After a graduation from a life science engineering school degree and a MSc in Human genetics and cellular biology, spent 15 years in the biotech/biopharma industry. Previously CEO of ILTOO Pharma, and COO of Alfact Innovation.
CLEMENT BERTHOLET
VP Corporate Development
After a MSc in Molecular Biology from Ecole Normale Supérieure de Cachan and a specialisation in epigenetics, spent 6 years as a Corps des Mines chief engineer in corporate finance and restructuring for the French Ministry of Economy and Finance.
STEPHANIE BEQ, PHD
R&D Director
After a PhD in immunological studies in the laboratory of Françoise Barre-Sinoussi (Nobel Price in 2008), spent 15 years of research and drug discovery & development in immunology. Previously Senior Director at HiFiBiO, Alexion, Stallergenes, and Cytheris.
24 publications & 2 Patents
SCIENTIFIC TEAM
Our scientific team consists of 3 scientific founders used to entrepreunarial experiences, who conducted academic research (at INSERM and AP-HP) over the past decade to identify the new target.
ERIC CHEVET, PHD
Co-founder
Research director at INSERM, head INSERM U1242,
Expert in endoplasmic reticulum biology,
193 publications (Pubmed),
H-index 60 (Google Scholar),
9 patents, Cofounder of Cell Stress Discoveries Ltd.
Co-editor in chief Traffic
ERIC OGIER-DENIS, PHD
Co-founder
Research director at INSERM
Expert in pathophysiology of IBD,
Partner Labex Inflamex Paris
82 publications (Pubmed),
H-index 45 (Google Scholar),
14 patents, Cofounder Inception IBD (Versant Ventures, Celgene)
XAVIER TRETON, MD-PHD
Co-founder
Professor of Gastroenterology at Beaujon Hospital, APHP, Paris,
Expert in IBD, clinical and translational research (Biomarkers)
84 publications (Pubmed)
H-index 27 (Google Scholar)
11 patents, Cofounder Inception IBD (Versant Ventures, Celgene)
Head of GI tissueBank, Beaujon Hospital